Merck Manual

Please confirm that you are a health care professional

honeypot link

Genetic Diagnostic Technologies


David N. Finegold

, MD, University of Pittsburgh

Last full review/revision Jul 2021| Content last modified Jul 2021
Click here for Patient Education

Genetic diagnostic technology is rapidly improving. A small amount of DNA can be amplified using the polymerase chain reaction (PCR) process, which can produce millions of copies of a gene or gene segments. RNA can be amplified by combining the reverse transcriptase (RT) enzyme with traditional PCR.

Gene probes can be used to locate specific segments of normal or mutated DNA. Different types of probes may investigate a broad range of sizes of DNA sequence. A known DNA segment may be cloned and then fluorescently tagged (using fluorescent in situ hybridization [FISH]); this segment is then combined with a test specimen. The tagged DNA binds to its complementary DNA segment and can be detected by measuring the amount and type of fluorescence. Gene probes can detect a number of disorders before and after birth.

Oligonucleotide arrays (probes) are another type of probe now routinely utilized to identify deleted or duplicated regions of DNA sequence in specific chromosomes on a genomewide basis. DNA from a patient is compared to a reference genome using many oligonucleotide probes. Using such probes, the entire genome can be tested (queried).

Microchips are powerful tools that can be used to identify DNA mutations, pieces of RNA, or proteins. A single chip can test for millions of different DNA changes using only one sample. Microchips provide finer resolution for genome queries than oligonucleotide arrays.

Next-generation sequencing technologies have dramatically changed the approach to genetic diagnosis. This technology involves breaking the entire genome into small segments, sequencing the segments, and then reassembling the sequences using intensive computational techniques to provide the base-by-base sequence of the entire genome or more limited regions, such as the expressed portion of the genome known as the exome. This process helps identify single or multiple nucleotide variations as well as areas of insertion or deletion. The costs of this technology have dramatically fallen and continue to fall. The equipment and computational methods also continue to improve.

This revolutionary and rapidly evolving technology has moved a significant portion of the technical aspects of genetic diagnosis to next-generation sequencing and has become the mainstay of genetic diagnosis. However, the sheer volume of information generated by sequencing the exome or genome results in a variety of interpretive problems that complicate understanding of the results. Despite these issues, these techniques appear to be the technology of the future.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read
Test your knowledge
The Dying Patient
If a patient is potentially dying, the patient should be as involved as possible with health-care decision making. However, if a patient lacks the ability to make health-care decisions and has no authorized surrogate, it is most appropriate to consult the patient’s spouse or domestic partner first. If the patient does not have a spouse or domestic partner, which of the following individuals is most appropriate to consult next? 
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID

Also of Interest